– ARCHIMED, a global private equity specialist focused exclusively on healthcare, announced the final close of MED IV at its €1.5 billion ($1.75 billion) hard cap.
– Launched in January 2026 with a €1.2 billion target, MED IV closed in less than six months and was three times oversubscribed.
– Denis Ribon, Chairman and Managing Partner at ARCHIMED, said: “Investors like our healthcare specialization, top-decile DPI track-record, our proven alpha-focused Playbook, the well-structured and scalable platform, and our transparent governance and stable ownership.”
– MED IV attracted a broad, largely institutional LP base, including pension funds, insurance companies and sovereign wealth funds, with strong participation from both existing and new investors.
– Baptiste Mélinon, Partner and Head of Investor Relations at ARCHIMED, said: “We’ve seen strong acceleration in Asia, while building on long-standing partnerships with our European and North American investors.”
– MED IV will primarily pursue majority control investments alongside founders, families and management teams across Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services and MedTech.
– ARCHIMED’s value creation strategy focuses on international expansion, innovation, operational scaling and active buy-and-build strategies to accelerate the growth of profitable healthcare companies.
